CycloSam Therapeutics, Inc. is a recent spinout of IsoTherapeutics Group, LLC. CycloSam® Sm-153 DOTMP is a new bone seeking patent pending radiopharmaceutical being developed for bone cancers, including palliation of pain from bone metastases or the treatment of primary bone tumors and secondary bone metastases, and for bone marrow ablation/transplant.
Liquid Brachytherapy Agent for Solid Inoperable Tumors
IsoTherapeutics, in collaboration with the Gabriel Institute and Valco Instruments Company, Inc. has developed a novel method to treat solid inoperable tumors. Traditional brachytherapy uses encapsulated gamma emitters and irradiation of non-target tissue is a big issue. Beta emitters, which would have a much smaller field of irradiation, have not been used in this manner because the capsules would effectively shield the beta particles. Use of beta emitters without encapsulation would normally result in the migration of isotope and thus radiation dose to non-target tissues. Liquid Brachytherapy involves a simple and effective chemical approach to immobilizing metallic radioisotopes. This technology is protected by PCT patent application WO 2009/045230. This technology is available for license.